{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:05:15Z","timestamp":1792555515857,"version":"4.5.0"},"reference-count":153,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.jaad.2019.11.042","type":"journal-article","created":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T11:33:47Z","timestamp":1575459227000},"page":"969-979","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["Botulinum toxin: Pharmacology and injectable administration for the treatment of primary hyperhidrosis"],"prefix":"10.1016","volume":"82","author":[{"given":"Shiri","family":"Nawrocki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jisun","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jaad.2019.11.042_bib1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1111\/j.1365-4632.2007.03266.x","article-title":"Screening for common dermatologic disorders amongst Israeli adolescents","volume":"46","author":"Wohl","year":"2007","journal-title":"Int J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2019.11.042_bib2","doi-asserted-by":"crossref","first-page":"e0153719","DOI":"10.1371\/journal.pone.0153719","article-title":"Hyperhidrosis prevalence and demographical characteristics in dermatology outpatients in Shanghai and Vancouver","volume":"11","author":"Liu","year":"2016","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.jaad.2019.11.042_bib3","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/1346-8138.12258","article-title":"Epidemiological study and considerations of primary focal hyperhidrosis in Japan: from questionnaire analysis","volume":"40","author":"Fujimoto","year":"2013","journal-title":"J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2019.11.042_bib4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000351292","article-title":"Prevalence and disease burden of hyperhidrosis in the adult population","volume":"227","author":"Augustin","year":"2013","journal-title":"Dermatology"},{"issue":"10","key":"10.1016\/j.jaad.2019.11.042_bib5","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/1346-8138.12238","article-title":"Is subjective hyperhidrosis assessment sufficient enough? prevalence of hyperhidrosis among young Polish adults","volume":"40","author":"Stefaniak","year":"2013","journal-title":"J Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2019.11.042_bib6","doi-asserted-by":"crossref","first-page":"e0220664","DOI":"10.1371\/journal.pone.0220664","article-title":"Primary hyperhidrosis prevalence and characteristics among medical students in Rio de Janeiro","volume":"14","author":"Ribeiro Santos Morard","year":"2019","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jaad.2019.11.042_bib7","first-page":"CC08","article-title":"A study on the impact of hyperhidrosis on the quality of life among college students","volume":"10","author":"Muthusamy","year":"2016","journal-title":"J Clin Diagn Res"},{"issue":"10","key":"10.1016\/j.jaad.2019.11.042_bib8","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00403-016-1697-9","article-title":"Hyperhidrosis: an update on prevalence and severity in the United States","volume":"308","author":"Doolittle","year":"2016","journal-title":"Arch Dermatol Res"},{"issue":"11","key":"10.1016\/j.jaad.2019.11.042_bib9","first-page":"729","article-title":"Hyperhidrosis: management options","volume":"97","author":"McConaghy","year":"2018","journal-title":"Am Fam Physician"},{"issue":"3","key":"10.1016\/j.jaad.2019.11.042_bib10","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jaad.2018.12.071","article-title":"The etiology, diagnosis, and management of hyperhidrosis: a comprehensive review: etiology and clinical work-up","volume":"81","author":"Nawrocki","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2019.11.042_bib11","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jaad.2003.12.029","article-title":"Recognition, diagnosis, and treatment of primary focal hyperhidrosis","volume":"51","author":"Hornberger","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2019.11.042_bib12","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jaad.2010.03.013","article-title":"Clinical differentiation of primary from secondary hyperhidrosis","volume":"64","author":"Walling","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2019.11.042_bib13","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.det.2014.06.006","article-title":"Incidence and prevalence of hyperhidrosis","volume":"32","author":"Moraites","year":"2014","journal-title":"Dermatol Clin"},{"issue":"6","key":"10.1016\/j.jaad.2019.11.042_bib14","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1001\/archderm.139.6.731","article-title":"Botulinum toxin type a is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study","volume":"139","author":"Naumann","year":"2003","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2019.11.042_bib15","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jaad.2007.01.009","article-title":"Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety","volume":"56","author":"Lowe","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2019.11.042_bib16","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/imj.13727","article-title":"Results of a 10-year follow-up study of botulinum toxin A therapy for primary axillary hyperhidrosis in Australia","volume":"48","author":"Rosen","year":"2018","journal-title":"Intern Med J"},{"issue":"4","key":"10.1016\/j.jaad.2019.11.042_bib17","first-page":"392","article-title":"Understanding patient experience with hyperhidrosis: a national survey of 1,985 patients","volume":"17","author":"Glaser","year":"2018","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2019.11.042_bib18","first-page":"1","article-title":"The treatment of primary focal hyperhidrosis","volume":"24","author":"Wechter","year":"2019","journal-title":"Skin Ther Lett"},{"issue":"5","key":"10.1016\/j.jaad.2019.11.042_bib19","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1111\/j.1365-2133.2004.06250.x","article-title":"BOTOX delivery by iontophoresis","volume":"151","author":"Kavanagh","year":"2004","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2019.11.042_bib20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1440-0960.2008.00441.x","article-title":"Effect and persistency of botulinum toxin iontophoresis in the treatment of palmar hyperhidrosis","volume":"49","author":"Davarian","year":"2008","journal-title":"Australas J Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2019.11.042_bib21","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jama.285.8.1059","article-title":"Botulinum toxin as a biological weapon: medical and public health management","volume":"285","author":"Arnon","year":"2001","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jaad.2019.11.042_bib22","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1128\/mr.46.1.86-94.1982","article-title":"Bacterial toxins: a table of lethal amounts","volume":"46","author":"Gill","year":"1982","journal-title":"Microbiol Rev"},{"issue":"4","key":"10.1016\/j.jaad.2019.11.042_bib23","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.resmic.2014.09.007","article-title":"Historical and current perspectives on Clostridium botulinum diversity","volume":"166","author":"Smith","year":"2015","journal-title":"Res Microbiol"},{"key":"10.1016\/j.jaad.2019.11.042_bib24","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0065-2911(09)05503-9","article-title":"Biology and genomic analysis of Clostridium botulinum","volume":"55","author":"Peck","year":"2009","journal-title":"Adv Microb Physiol"},{"issue":"8","key":"10.1016\/j.jaad.2019.11.042_bib25","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrmicro3295","article-title":"Botulinum neurotoxins: genetic, structural and mechanistic insights","volume":"12","author":"Rossetto","year":"2014","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"10.1016\/j.jaad.2019.11.042_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40268-014-0077-1","article-title":"Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products","volume":"15","author":"Frevert","year":"2015","journal-title":"Drugs R D"},{"issue":"Pt A","key":"10.1016\/j.jaad.2019.11.042_bib27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.toxicon.2015.09.009","article-title":"The long journey of botulinum neurotoxins into the synapse","volume":"107","author":"Rummel","year":"2015","journal-title":"Toxicon"},{"issue":"23","key":"10.1016\/j.jaad.2019.11.042_bib28","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1080\/09638280701568296","article-title":"Pharmacology of therapeutic botulinum toxin preparations","volume":"29","author":"Dressler","year":"2007","journal-title":"Disabil Rehabil"},{"issue":"7019","key":"10.1016\/j.jaad.2019.11.042_bib29","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/nature03123","article-title":"Substrate recognition strategy for botulinum neurotoxin serotype A","volume":"432","author":"Breidenbach","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2019.11.042_bib30","first-page":"139","article-title":"Clostridial neurotoxin light chains: devices for SNARE cleavage mediated blockade of neurotransmission","volume":"364","author":"Binz","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"issue":"5","key":"10.1016\/j.jaad.2019.11.042_bib31","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00018-013-1380-7","article-title":"The blockade of the neurotransmitter release apparatus by botulinum neurotoxins","volume":"71","author":"Pantano","year":"2014","journal-title":"Cell Mol Life Sci"},{"issue":"6505","key":"10.1016\/j.jaad.2019.11.042_bib32","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/372415a0","article-title":"SNARE motif and neurotoxins","volume":"372","author":"Rossetto","year":"1994","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.jaad.2019.11.042_bib33","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1073\/pnas.96.6.3200","article-title":"Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals","volume":"96","author":"de Paiva","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5-8","key":"10.1016\/j.jaad.2019.11.042_bib34","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1023\/B:NEUR.0000020634.59639.cf","article-title":"Cytokines, growth factors and sprouting at the neuromuscular junction","volume":"32","author":"English","year":"2003","journal-title":"J Neurocytol"},{"issue":"1","key":"10.1016\/j.jaad.2019.11.042_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cne.21439","article-title":"Distinct patterns of motor nerve terminal sprouting induced by ciliary neurotrophic factor vs. botulinum toxin","volume":"504","author":"Wright","year":"2007","journal-title":"J Comp Neurol"},{"issue":"5","key":"10.1016\/j.jaad.2019.11.042_bib36","first-page":"964","article-title":"Motor nerve sprouting in human orbicularis muscle after botulinum A injection","volume":"31","author":"Holds","year":"1990","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"16","key":"10.1016\/j.jaad.2019.11.042_bib37","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.4103\/1673-5374.139479","article-title":"Acrylamide inhibits nerve sprouting induced by botulinum toxin type A","volume":"9","author":"Jiang","year":"2014","journal-title":"Neural Regen Res"},{"issue":"1","key":"10.1016\/j.jaad.2019.11.042_bib38","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1590\/S0004-282X2005000100035","article-title":"Botulinum toxin: mechanisms of action","volume":"63","author":"Dressler","year":"2005","journal-title":"Arq Neuropsiquiatr"},{"issue":"1-2","key":"10.1016\/j.jaad.2019.11.042_bib39","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0928-4257(01)00086-9","article-title":"Botulinum neurotoxins: from paralysis to recovery of functional neuromuscular transmission","volume":"96","author":"Meunier","year":"2002","journal-title":"J Physiol Paris"},{"issue":"5","key":"10.1016\/j.jaad.2019.11.042_bib40","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/jor.20131","article-title":"How muscles recover from paresis and atrophy after intramuscular injection of botulinum toxin A: study in juvenile rats","volume":"24","author":"Shen","year":"2006","journal-title":"J Orthop Res"},{"issue":"2","key":"10.1016\/j.jaad.2019.11.042_bib41","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1167\/iovs.10-6427","article-title":"Modulating neuromuscular junction density changes in botulinum toxin-treated orbicularis oculi muscle","volume":"52","author":"Harrison","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.jaad.2019.11.042_bib42","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0304-3940(98)00775-7","article-title":"Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans","volume":"256","author":"Eleopra","year":"1998","journal-title":"Neurosci Lett"},{"issue":"12","key":"10.1016\/j.jaad.2019.11.042_bib43","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/S0149-2918(00)83049-0","article-title":"Duration of effect of botulinum toxin type A in adult patients with cervical dystonia: a retrospective chart review","volume":"22","author":"Brashear","year":"2000","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.jaad.2019.11.042_bib44","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/0974-2077.41148","article-title":"Botulinum toxin: non-cosmetic indications and possible mechanisms of action","volume":"1","author":"Wollina","year":"2008","journal-title":"J Cutan Aesthet Surg"},{"issue":"4","key":"10.1016\/j.jaad.2019.11.042_bib45","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00702-007-0812-7","article-title":"Evidence for effectiveness of botulinum toxin for hyperhidrosis","volume":"115","author":"Bhidayasiri","year":"2008","journal-title":"J Neural Transm (Vienna)"},{"issue":"6","key":"10.1016\/j.jaad.2019.11.042_bib46","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00266-011-9738-4","article-title":"Treatment of axillary hyperhidrosis with botulinum toxin: a single surgeon's experience with 53 consecutive patients","volume":"35","author":"Doft","year":"2011","journal-title":"Aesthet Plast Surg"},{"issue":"4","key":"10.1016\/j.jaad.2019.11.042_bib47","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1365-2133.2009.09248.x","article-title":"Botulinum toxin abolishes sweating via impaired sweat gland responsiveness to exogenous acetylcholine","volume":"161","author":"Shibasaki","year":"2009","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2019.11.042_bib48","first-page":"799","article-title":"Repetitive injections of botulinum toxin A continuously increase the duration of efficacy in primary axillary hyperhidrosis: a retrospective analysis in 101 patients","volume":"13","author":"Brehmer","year":"2015","journal-title":"J Dtsch Dermatol Ges"},{"issue":"6","key":"10.1016\/j.jaad.2019.11.042_bib49","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jaad.2013.08.002","article-title":"Duration of efficacy increases with the repetition of botulinum toxin A injections in primary axillary hyperhidrosis: a study in 83 patients","volume":"69","author":"Lecouflet","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"31","key":"10.1016\/j.jaad.2019.11.042_bib50","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.2174\/138161209789271843","article-title":"Current clinical applications of botulinum toxin","volume":"15","author":"Truong","year":"2009","journal-title":"Curr Pharm Des"},{"issue":"5","key":"10.1016\/j.jaad.2019.11.042_bib51","doi-asserted-by":"crossref","first-page":"E208","DOI":"10.3390\/toxins10050208","article-title":"The expanding therapeutic utility of botulinum neurotoxins","volume":"10","author":"Fonfria","year":"2018","journal-title":"Toxins"},{"key":"10.1016\/j.jaad.2019.11.042_bib52","author":"Allergan"},{"key":"10.1016\/j.jaad.2019.11.042_bib53","author":"Ipsen Biopharm"},{"key":"10.1016\/j.jaad.2019.11.042_bib54","author":"Merz Pharmaceuticals"},{"key":"10.1016\/j.jaad.2019.11.042_bib55","author":"Evolus"},{"key":"10.1016\/j.jaad.2019.11.042_bib56","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1097\/DSS.0000000000001903","article-title":"Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies","volume":"45","author":"Beer","year":"2019","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2019.11.042_bib57","author":"Solstice Neurosciences"},{"key":"10.1016\/j.jaad.2019.11.042_bib58","series-title":"Botulinum Toxin: Procedures in Cosmetic Dermatology Series","first-page":"177","article-title":"Focal axillary hyperhidrosis","author":"Glaser","year":"2018"},{"key":"10.1016\/j.jaad.2019.11.042_bib59","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.tox.2013.02.006","article-title":"Botulinum toxins: mechanisms of action, antinociception and clinical applications","volume":"306","author":"Wheeler","year":"2013","journal-title":"Toxicology"},{"key":"10.1016\/j.jaad.2019.11.042_bib60","first-page":"325","article-title":"Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?","volume":"4","author":"Frevert","year":"2010","journal-title":"Biologics"},{"key":"10.1016\/j.jaad.2019.11.042_bib61","first-page":"21","article-title":"Assembly and function of the botulinum neurotoxin progenitor complex","volume":"364","author":"Gu","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"issue":"2","key":"10.1016\/j.jaad.2019.11.042_bib62","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2165\/11584780-000000000-00000","article-title":"Content of botulinum neurotoxin in Botox\u00ae\/Vistabel\u00ae, Dysport\u00ae\/Azzalure\u00ae, and Xeomin\u00ae\/Bocouture\u00ae","volume":"10","author":"Frevert","year":"2010","journal-title":"Drugs R D"},{"issue":"4","key":"10.1016\/j.jaad.2019.11.042_bib63","first-page":"455","article-title":"Botulinum toxins: pharmacology and its current therapeutic evidence for use","volume":"51","author":"Panicker","year":"2003","journal-title":"Neurol India"},{"issue":"6","key":"10.1016\/j.jaad.2019.11.042_bib64","first-page":"1","article-title":"Botulinum toxin products overview","volume":"13","author":"Carruthers","year":"2008","journal-title":"Skin Ther Lett"},{"issue":"2 Pt 1","key":"10.1016\/j.jaad.2019.11.042_bib65","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1067\/mjd.2000.105567","article-title":"Pharmacology of botulinum toxin","volume":"43","author":"Huang","year":"2000","journal-title":"J Am Acad Dermatol"},{"issue":"1 suppl","key":"10.1016\/j.jaad.2019.11.042_bib66","first-page":"18s","article-title":"IncobotulinumtoxinA (Xeomin): background, mechanism of action, and manufacturing","volume":"33","author":"Lorenc","year":"2013","journal-title":"Aesthet Surg J"},{"issue":"3","key":"10.1016\/j.jaad.2019.11.042_bib67","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.mib.2012.05.012","article-title":"Clinical applications of botulinum toxin","volume":"15","author":"Dressler","year":"2012","journal-title":"Curr Opin Microbiol"},{"issue":"3","key":"10.1016\/j.jaad.2019.11.042_bib68","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/01.IOP.0000129012.09632.49","article-title":"Increased patient comfort utilizing botulinum toxin type a reconstituted with preserved versus nonpreserved saline","volume":"20","author":"Kwiat","year":"2004","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"6","key":"10.1016\/j.jaad.2019.11.042_bib69","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/j.1524-4725.2011.02284.x","article-title":"Pain difference associated with injection of abobotulinumtoxinA reconstituted with preserved saline and preservative-free saline: a prospective, randomized, side-by-side, double-blind study","volume":"38","author":"Allen","year":"2012","journal-title":"Dermatol Surg"},{"issue":"3","key":"10.1016\/j.jaad.2019.11.042_bib70","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jaad.2011.10.008","article-title":"Recommendations and current practices for the reconstitution and storage of botulinum toxin type A","volume":"67","author":"Liu","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2019.11.042_bib71","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00266-004-0062-0","article-title":"Evaluating effects of preservative-containing saline solution on pain perception during botulinum toxin type-a injections at different locations: a prospective, single-blinded, randomized controlled trial","volume":"29","author":"Sarifakioglu","year":"2005","journal-title":"Aesthet Plast Surg"},{"issue":"5","key":"10.1016\/j.jaad.2019.11.042_bib72","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/j.1365-2133.2007.07760.x","article-title":"Treatment of axillary hyperhidrosis with botulinum toxin type A reconstituted in lidocaine or in normal saline: a randomized, side-by-side, double-blind study","volume":"156","author":"Vadoud-Seyedi","year":"2007","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2019.11.042_bib73","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1468-3083.2011.04066.x","article-title":"Dilution of botulinum toxin A in lidocaine vs. in normal saline for the treatment of primary axillary hyperhidrosis: a double-blind, randomized, comparative preliminary study","volume":"26","author":"Gulec","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.jaad.2019.11.042_bib74","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00702-016-1522-9","article-title":"Botulinum toxin therapy: reduction of injection site pain by pH normalisation","volume":"123","author":"Dressler","year":"2016","journal-title":"J Neural Transm (Vienna)"},{"issue":"3","key":"10.1016\/j.jaad.2019.11.042_bib75","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/DSS.0000000000000303","article-title":"Consensus statement regarding storage and reuse of previously reconstituted neuromodulators","volume":"41","author":"Alam","year":"2015","journal-title":"Dermatol Surg"},{"issue":"6","key":"10.1016\/j.jaad.2019.11.042_bib76","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/j.1524-4725.2009.01158.x","article-title":"Blind multicenter study of the efficacy and safety of injections of a commercial preparation of botulinum toxin type A reconstituted up to 15 days before injection","volume":"35","author":"Hexsel","year":"2009","journal-title":"Dermatol Surg"},{"issue":"2","key":"10.1016\/j.jaad.2019.11.042_bib77","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/asj\/sju072","article-title":"Absence of bacterial or fungal growth in vials of reconstituted botulinum toxin type A after storage","volume":"35","author":"Osaki","year":"2015","journal-title":"Aesthet Surg J"},{"issue":"4","key":"10.1016\/j.jaad.2019.11.042_bib78","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1001\/archfaci.10.4.273","article-title":"Questioning the need to use Botox within 4 hours of reconstitution: a study of fresh vs 2-week-old Botox","volume":"10","author":"Yang","year":"2008","journal-title":"Arch Facial Plast Surg"},{"issue":"5","key":"10.1016\/j.jaad.2019.11.042_bib79","first-page":"523","article-title":"Multicenter, double-blind study of the efficacy of injections with botulinum toxin type A reconstituted up to six consecutive weeks before application","volume":"29","author":"Hexsel","year":"2003","journal-title":"Dermatol Surg"},{"issue":"2","key":"10.1016\/j.jaad.2019.11.042_bib80","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s00266-006-0161-1","article-title":"Reconstituted botulinum type A neurotoxin: clinical efficacy after long-term freezing before use","volume":"31","author":"Parsa","year":"2007","journal-title":"Aesthet Plast Surg"},{"issue":"suppl 1","key":"10.1016\/j.jaad.2019.11.042_bib81","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1468-1331.2006.01438.x","article-title":"Pharmacology of botulinum toxin: differences between type A preparations","volume":"13","author":"Rosales","year":"2006","journal-title":"Eur J Neurol"},{"issue":"3","key":"10.1016\/j.jaad.2019.11.042_bib82","doi-asserted-by":"crossref","DOI":"10.3390\/toxins8030065","article-title":"Conversion ratio between Botox\u00ae, Dysport\u00ae, and Xeomin\u00ae in clinical practice","volume":"8","author":"Scaglione","year":"2016","journal-title":"Toxins (Basel)"},{"issue":"1","key":"10.1016\/j.jaad.2019.11.042_bib83","doi-asserted-by":"crossref","first-page":"7","DOI":"10.11138\/FNeur\/2018.33.1.007","article-title":"Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal","volume":"33","author":"Ferrari","year":"2018","journal-title":"Funct Neurol"},{"key":"10.1016\/j.jaad.2019.11.042_bib84","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.neulet.2016.06.001","article-title":"In-vivo comparison of the neurotoxic potencies of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA","volume":"627","author":"Kutschenko","year":"2016","journal-title":"Neurosci Lett"},{"issue":"2","key":"10.1016\/j.jaad.2019.11.042_bib85","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jaad.2008.12.028","article-title":"Botox and Dysport: is there a dose conversion ratio in dermatology and aesthetic medicine?","volume":"62","author":"Karsai","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.11.042_bib86","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.toxicon.2008.04.029","article-title":"Equivalent potency of Xeomin\u00ae and BOTOX\u00ae","volume":"51","author":"Dirk","year":"2008","journal-title":"Toxicon"},{"issue":"3","key":"10.1016\/j.jaad.2019.11.042_bib87","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2340\/00015555-1464","article-title":"Botulinum toxin type A and B improve quality of life in patients with axillary and palmar hyperhidrosis","volume":"93","author":"Rosell","year":"2013","journal-title":"Acta Derm Venereol"},{"issue":"8","key":"10.1016\/j.jaad.2019.11.042_bib88","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1097\/DSS.0000000000000429","article-title":"Comparison of onabotulinumtoxinA and rimabotulinumtoxinB for the treatment of axillary hyperhidrosis","volume":"41","author":"An","year":"2015","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2019.11.042_bib89","author":"Brodsky","year":"2012"},{"issue":"6","key":"10.1016\/j.jaad.2019.11.042_bib90","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/j.1365-2133.2004.06317.x","article-title":"The place of botulinum toxin type A in the treatment of focal hyperhidrosis","volume":"151","author":"Lowe","year":"2004","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2019.11.042_bib91","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jaad.2016.11.022","article-title":"Injectable and topical neurotoxins in dermatology: basic science, anatomy, and therapeutic agents","volume":"76","author":"Giordano","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2019.11.042_bib92","first-page":"497","article-title":"Efficacy of botulinum toxin type B for the treatment of primary palmar hyperhidrosis: a prospective, open, single-blind, multi-centre study","volume":"306","author":"Basciani","year":"2014","journal-title":"Arch Dermatol Res"},{"issue":"5","key":"10.1016\/j.jaad.2019.11.042_bib93","first-page":"519","article-title":"Botulinum toxin type B (MYOBLOC) versus botulinum toxin type A (BOTOX) frontalis study: rate of onset and radius of diffusion","volume":"29","author":"Flynn","year":"2003","journal-title":"Dermatol Surg"},{"issue":"1","key":"10.1016\/j.jaad.2019.11.042_bib94","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.clindermatol.2003.11.005","article-title":"Botulinum toxin types A and B: comparison of efficacy, duration, and dose-ranging studies for the treatment of facial rhytides and hyperhidrosis","volume":"22","author":"Yamauchi","year":"2004","journal-title":"Clin Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2019.11.042_bib95","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s00415-002-0929-4","article-title":"Botulinum toxin type B for treatment of axillar hyperhidrosis","volume":"249","author":"Dressler","year":"2002","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.jaad.2019.11.042_bib96","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.bjps.2004.07.003","article-title":"Botulinum toxin type B: a new therapy for axillary hyperhidrosis","volume":"58","author":"Nelson","year":"2005","journal-title":"Br J Plast Surg"},{"issue":"2","key":"10.1016\/j.jaad.2019.11.042_bib97","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1001\/archderm.139.2.226","article-title":"Systemic adverse effects after botulinum toxin type B (myobloc) injections for the treatment of palmar hyperhidrosis","volume":"139","author":"Baumann","year":"2003","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2019.11.042_bib98","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clindermatol.2003.11.001","article-title":"Botulinum toxin-B and the management of hyperhidrosis","volume":"22","author":"Baumann","year":"2004","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaad.2019.11.042_bib99","first-page":"315","article-title":"Autonomic side effects of botulinum toxin type B therapy","volume":"94","author":"Dressler","year":"2004","journal-title":"Adv Neurol"},{"issue":"suppl 8","key":"10.1016\/j.jaad.2019.11.042_bib100","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1002\/mds.20020","article-title":"Basic immunological aspects of botulinum toxin therapy","volume":"19","author":"Atassi","year":"2004","journal-title":"Mov Disord"},{"issue":"suppl 1","key":"10.1016\/j.jaad.2019.11.042_bib101","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1468-1331.2006.01439.x","article-title":"Immunological aspects of Botox, Dysport and Myobloc\/NeuroBloc","volume":"13","author":"Dressler","year":"2006","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jaad.2019.11.042_bib102","author":"Brannon"},{"key":"10.1016\/j.jaad.2019.11.042_bib103","author":"Allergan"},{"key":"10.1016\/j.jaad.2019.11.042_bib104","series-title":"Botulinum Toxins: Cosmetic and Clinical Applications","first-page":"285","article-title":"Axillary hyperhidrosis","author":"de Almeida","year":"2017"},{"key":"10.1016\/j.jaad.2019.11.042_bib105","series-title":"Botulinum Toxins: Cosmetic and Clinical Applications","first-page":"299","article-title":"Primary focal palm, sole, craniofacial, and compensatory hyperhidrosis","author":"Glaser","year":"2017"},{"key":"10.1016\/j.jaad.2019.11.042_bib106","series-title":"Botulinum Toxins: Cosmetic and Clinical Applications","first-page":"357","article-title":"OnabotulinumtoxinA (Botox\u00ae) in dermatology","author":"Emer","year":"2017"},{"issue":"5 suppl","key":"10.1016\/j.jaad.2019.11.042_bib107","first-page":"18","article-title":"Palmar and plantar hyperhidrosis: best practice recommendations and special considerations","volume":"79","author":"Glaser","year":"2007","journal-title":"Cutis"},{"issue":"11","key":"10.1016\/j.jaad.2019.11.042_bib108","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/j.1524-4725.2011.02087.x","article-title":"Handling botulinum toxins: an updated literature review","volume":"37","author":"Trindade De Almeida","year":"2011","journal-title":"Dermatol Surg"},{"issue":"1","key":"10.1016\/j.jaad.2019.11.042_bib109","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.clindermatol.2003.11.007","article-title":"Hyperhidrosis and botulinum toxin A: patient selection and techniques","volume":"22","author":"Glogau","year":"2004","journal-title":"Clin Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2019.11.042_bib110","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2165\/00128071-200910020-00002","article-title":"Botulinum toxin for hyperhidrosis: a review","volume":"10","author":"Grunfeld","year":"2009","journal-title":"Am J Clin Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2019.11.042_bib111","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1001\/archderm.141.10.1255","article-title":"Low-dose efficacy of botulinum toxin A for axillary hyperhidrosis: a randomized, side-by-side, open-label study","volume":"141","author":"Heckmann","year":"2005","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2019.11.042_bib112","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1055\/s-0035-1571213","article-title":"Botulinum toxin: preparations for clinical use, immunogenicity, side effects, and safety profile","volume":"36","author":"Dashtipour","year":"2016","journal-title":"Semin Neurol"},{"issue":"7","key":"10.1016\/j.jaad.2019.11.042_bib113","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM200102153440704","article-title":"Botulinum toxin A for axillary hyperhidrosis (excessive sweating)","volume":"344","author":"Heckmann","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2019.11.042_bib114","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.toxicon.2012.10.020","article-title":"Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders","volume":"67","author":"Naumann","year":"2013","journal-title":"Toxicon"},{"issue":"9","key":"10.1016\/j.jaad.2019.11.042_bib115","first-page":"822","article-title":"Efficacy and safety of botulinum toxin type a in the treatment of palmar hyperhidrosis: a double-blind, randomized, placebo-controlled study","volume":"28","author":"Lowe","year":"2002","journal-title":"Dermatol Surg"},{"issue":"5","key":"10.1016\/j.jaad.2019.11.042_bib116","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/j.1365-2133.2003.05620.x","article-title":"A double-blind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosis","volume":"149","author":"Simonetta Moreau","year":"2003","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2019.11.042_bib117","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1473-2165.2005.00304.x","article-title":"Treatment of palmar hyperhidrosis with botulinum toxin type A: 44 months of experience","volume":"4","author":"Perez-Bernal","year":"2005","journal-title":"J Cosmet Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2019.11.042_bib118","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1067\/mjd.2000.105156","article-title":"Botulinum toxin type A therapy for palmar and digital hyperhidrosis","volume":"42","author":"Solomon","year":"2000","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2019.11.042_bib119","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1524-4725.2009.01140.x","article-title":"Botulinum toxin: a treatment for compensatory hyperhidrosis in the trunk","volume":"35","author":"Kim","year":"2009","journal-title":"Dermatol Surg"},{"issue":"2","key":"10.1016\/j.jaad.2019.11.042_bib120","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4103\/0378-6323.93647","article-title":"Hyperhidrosis of face and scalp: repeated successful treatment with botulinum toxin type A","volume":"78","author":"Komericki","year":"2012","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"suppl 2","key":"10.1016\/j.jaad.2019.11.042_bib121","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1468-1331.2009.02877.x","article-title":"Routine use of Xeomin in patients previously treated with Botox: long term results","volume":"16","author":"Dressler","year":"2009","journal-title":"Eur J Neurol"},{"issue":"3","key":"10.1016\/j.jaad.2019.11.042_bib122","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00702-010-0372-0","article-title":"Comparing Botox and Xeomin for axillar hyperhidrosis","volume":"117","author":"Dressler","year":"2010","journal-title":"J Neural Transm (Vienna)"},{"issue":"6","key":"10.1016\/j.jaad.2019.11.042_bib123","first-page":"751","article-title":"Efficacy of botulinum toxin type A in the treatment of focal axillary hyperhidrosis","volume":"34","author":"Absar","year":"2008","journal-title":"Dermatol Surg"},{"issue":"3","key":"10.1016\/j.jaad.2019.11.042_bib124","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jaad.2005.06.011","article-title":"Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases","volume":"53","author":"Cote","year":"2005","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2019.11.042_bib125","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1185\/030079904125003962","article-title":"Safety of botulinum toxin type A: a systematic review and meta-analysis","volume":"20","author":"Naumann","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jaad.2019.11.042_bib126","series-title":"Botulinum Toxin: Procedures in Cosmetic Dermatology Series","first-page":"187","article-title":"Palmoplantar hyperhidrosis","author":"Mariwalla","year":"2018"},{"issue":"6","key":"10.1016\/j.jaad.2019.11.042_bib127","first-page":"873","article-title":"Cryoanalgesia with dichlorotetrafluoroethane spray versus ice packs in patients treated with botulinum toxin-a for palmar hyperhidrosis: self-controlled study","volume":"32","author":"Kontochristopoulos","year":"2006","journal-title":"Dermatol Surg"},{"issue":"1 spec no.","key":"10.1016\/j.jaad.2019.11.042_bib128","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1111\/j.1524-4725.2006.32337.x","article-title":"Ice minimizes discomfort associated with injection of botulinum toxin type A for the treatment of palmar and plantar hyperhidrosis","volume":"33","author":"Smith","year":"2007","journal-title":"Dermatol Surg"},{"issue":"5","key":"10.1016\/j.jaad.2019.11.042_bib129","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2310\/7750.2009.08072","article-title":"Ethyl chloride spray for sensory relief for botulinum toxin injections of the hands and feet","volume":"13","author":"Richards","year":"2009","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.jaad.2019.11.042_bib130","series-title":"Botulinum Toxin in Clinical Dermatology","first-page":"281","article-title":"Botulinum toxin in the management of focal hyperhidrosis","author":"Kreyden","year":"2006"},{"issue":"3","key":"10.1016\/j.jaad.2019.11.042_bib131","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1365-2133.2007.07691.x","article-title":"Needle-free anaesthesia prior to botulinum toxin type A injection treatment of palmar and plantar hyperhidrosis","volume":"156","author":"Benohanian","year":"2007","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2019.11.042_bib132","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jconrel.2012.11.010","article-title":"Pocketed microneedles for rapid delivery of a liquid-state botulinum toxin A formulation into human skin","volume":"165","author":"Torrisi","year":"2013","journal-title":"J Control Release"},{"issue":"4","key":"10.1016\/j.jaad.2019.11.042_bib133","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1067\/mjd.2001.110641","article-title":"Mechanoanesthesia to reduce the pain of local injections","volume":"44","author":"Reed","year":"2001","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2019.11.042_bib134","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1046\/j.1365-2133.2001.04104.x","article-title":"Intravenous regional anaesthesia for treatment of palmar hyperhidrosis with botulinum toxin type A","volume":"144","author":"Vollert","year":"2001","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2019.11.042_bib135","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1067\/mjd.2003.33","article-title":"Intravenous regional anesthesia (Bier's block) is superior to a peripheral nerve block for painless treatment of plantar hyperhidrosis with botulinum toxin","volume":"48","author":"Blaheta","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2019.11.042_bib136","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jaad.2003.09.006","article-title":"Local neural block at the wrist for treatment of palmar hyperhidrosis with botulinum toxin: technical improvements","volume":"51","author":"Campanati","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2019.11.042_bib137","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1046\/j.1365-2133.2003.05593.x","article-title":"A review of peripheral nerve blockade as local anaesthesia in the treatment of palmar hyperhidrosis","volume":"149","author":"Hayton","year":"2003","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2019.11.042_bib138","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1524-4725.2001.00157.x","article-title":"Improving botulinum toxin therapy for palmar hyperhidrosis: wrist block and technical considerations","volume":"27","author":"de Almeida","year":"2001","journal-title":"Dermatol Surg"},{"issue":"4","key":"10.1016\/j.jaad.2019.11.042_bib139","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1159\/000051780","article-title":"Treatment of idiopathic palmar hyperhidrosis with botulinum toxin. Report of 23 cases and review of the literature","volume":"203","author":"Vadoud-Seyedi","year":"2001","journal-title":"Dermatology"},{"issue":"2","key":"10.1016\/j.jaad.2019.11.042_bib140","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0733-8635(03)00122-0","article-title":"Complications with the use of botulinum toxin","volume":"22","author":"Klein","year":"2004","journal-title":"Dermatol Clin"},{"issue":"1","key":"10.1016\/j.jaad.2019.11.042_bib141","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.clindermatol.2003.12.026","article-title":"Contraindications and complications with the use of botulinum toxin","volume":"22","author":"Klein","year":"2004","journal-title":"Clin Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2019.11.042_bib142","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1046\/j.1468-1331.2000.00014.x","article-title":"Palmar and axillary hyperhidrosis treated with botulinum toxin: one-year clinical follow-up","volume":"7","author":"Naver","year":"2000","journal-title":"Eur J Neurol"},{"issue":"12","key":"10.1016\/j.jaad.2019.11.042_bib143","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/j.1365-4632.2004.02304.x","article-title":"Treatment of plantar hyperhidrosis with botulinum toxin type A","volume":"43","author":"Vadoud-Seyedi","year":"2004","journal-title":"Int J Dermatol"},{"issue":"5 suppl","key":"10.1016\/j.jaad.2019.11.042_bib144","first-page":"29","article-title":"Facial hyperhidrosis: best practice recommendations and special considerations","volume":"79","author":"Glaser","year":"2007","journal-title":"Cutis"},{"issue":"1","key":"10.1016\/j.jaad.2019.11.042_bib145","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/bjd.12568","article-title":"Botulinum toxin for focal hyperhidrosis of the face","volume":"170","author":"George","year":"2014","journal-title":"Br J Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2019.11.042_bib146","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s004150070073","article-title":"Botulinum toxin for treatment of craniofacial hyperhidrosis","volume":"247","author":"Boger","year":"2000","journal-title":"J Neurol"},{"issue":"4","key":"10.1016\/j.jaad.2019.11.042_bib147","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.clinthera.2007.04.015","article-title":"Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials","volume":"29","author":"Yablon","year":"2007","journal-title":"Clin Ther"},{"issue":"5","key":"10.1016\/j.jaad.2019.11.042_bib148","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00702-009-0223-z","article-title":"Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity","volume":"116","author":"Muller","year":"2009","journal-title":"J Neural Transm (Vienna)"},{"issue":"13","key":"10.1016\/j.jaad.2019.11.042_bib149","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1002\/mds.23254","article-title":"Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX\u00ae) across multiple indications","volume":"25","author":"Naumann","year":"2010","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.jaad.2019.11.042_bib150","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1006\/exnr.1997.6580","article-title":"Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies\u2014therapeutic consequences","volume":"147","author":"Goschel","year":"1997","journal-title":"Exp Neurol"},{"issue":"2","key":"10.1016\/j.jaad.2019.11.042_bib151","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00702-012-0893-9","article-title":"Immunogenicity of botulinum toxins","volume":"120","author":"Naumann","year":"2013","journal-title":"J Neural Transm (Vienna)"},{"key":"10.1016\/j.jaad.2019.11.042_bib152","first-page":"11","article-title":"Neutralizing antibodies to botulinum neurotoxin type A in aesthetic medicine: five case reports","volume":"7","author":"Torres","year":"2014","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2019.11.042_bib153","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1177\/1090820X11434506","article-title":"Treatment of hyperhidrosis with botulinum toxin","volume":"32","author":"Doft","year":"2012","journal-title":"Aesthet Surg J"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219331342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219331342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:53:20Z","timestamp":1759272800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962219331342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":153,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0190962219331342"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2019.11.042","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Botulinum toxin: Pharmacology and injectable administration for the treatment of primary hyperhidrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2019.11.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}